This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi center, single arm, prospective registry trial. Physicians control trial, conducted my N Sakai, Kobe City Medical Center General Hospital.

This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi center, single arm, prospective registry trial. Physicians control trial, conducted my N Sakai, Kobe City Medical Center General Hospital.

60 cases will be enrolled and 90 days follow up need. Primary endpoint is favorable clinical outcome, mRS 0-2. Secondary endpoint are mortality in 90days, immediate successful recanalization, TICI 2b-3, symptomatic intracranial hemorrhage, and any adverse event related to device and or procedure.

Inclusion Criteria:

• acute onset neurological sympto m related to occluded vessel
• within 8 hours from onset to tre atment or within 24 hours from onset to treatment with imaging diagnosis
• contra-indication or failed to int ravenous rt-PA
• accessible occlusion at ICA, MC A, VA, BA, PCA
• 5-30 of NIHSS
• 0-2 of mRS before onset
• obtain documented informed co ntent

Exclusion Criteria:

• following condition; arterial diss ection, engird, inaccessible turtuousity, difficult access by 50% or m ore stenosis, acute intracranial hemorrhage, space occuping lesion or brain tumor, major early ischemic change in brain
• occlude 2 major vessel territory
• allege for contrast media,
• abnormal PTT/APTT within 4 h ours intravenous heparin
• hemorrhagic tendency or 3 or more INR with Warfarin administration
• 30000cc or less of Platelet
• 50mg/dL or less of blood sugar
• uncontrolled blood pressure, 185mmHg or more at systolic, 110m mHg or more at diastolic
• 90days or less life expancy
• pregnant or lactating
• join another trial of medicine or medical device
• ineligible for trial